Early transcriptional responses in mouse embryos as a basis for selection of molecular markers predictive of valproic acid teratogenicity

Reproductive Toxicology

Volumn 30, Issue 3, 2010, Pages 457-468

  Kultima, Kim ^a   Jergil, Måns ^a   Salter, Hugh ^a,b   Gustafson, Anne Lee ^b   Dencker, Lennart ^a   Stigson, Michael ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Gene Ontology; In vitro toxicology; Microarray; Mouse embryo; Neural tube defects; Teratogen; Toxicogenomics; Valproic acid

Indexed keywords

CYTOCHROME P450 26A1; FIBROBLAST GROWTH FACTOR 15; GAP JUNCTION MEMBRANE CHANNEL PROTEIN ALPHA 1; HISTONE H1; HUNTINGTIN ASSOCIATED PROTEIN 1; LIN7 HOMOLOG B PROTEIN; MEMBRANE PROTEIN; SAL LIKE 2 PROTEIN; TRANSCRIPTION FACTOR OTX2; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; EMBRYO; EMBRYO CELL; EMBRYOTOXICITY; FEMALE; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PRENATAL DRUG EXPOSURE; TERATOGENESIS; TERATOGENICITY;

ANIMAL TESTING ALTERNATIVES; ANIMALS; BIOLOGICAL MARKERS; EMBRYONIC DEVELOPMENT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PREGNANCY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TERATOGENS; TRANSCRIPTION, GENETIC; VALPROIC ACID;

ANIMALIA;

EID: 77956442714     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reprotox.2010.05.014     Document Type: Article

References (52)

1. Stigson M., et al. Molecular targets and early response biomarkers for the prediction of developmental toxicity in vitro. Altern Lab Anim 2007, 35(3):335-342.
2. Kultima K., et al. Valproic acid teratogenicity: a toxicogenomics approach. Environ Health Perspect 2004, 112(12):1225-1235.
3. Jergil M., et al. Valproic acid-induced deregulation in vitro of genes associated in vivo with neural tube defects. Toxicol Sci 2009, 108(1):132-148.
4. Nau H., Hauck R.S., Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 1991, 69(5):310-321.
5. Menegola E., et al. Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Teratog Carcinog Mutagen 1996, 16(2):97-108.
6. Massa V., et al. Valproic acid-induced skeletal malformations: associated gene expression cascades. Pharmacogenet Genom 2005, 15(11):787-800.
7. Copp A.J., Greene N.D., Murdoch J.N. The genetic basis of mammalian neurulation. Nat Rev Genet 2003, 4(10):784-793.
8. Harris M.J., Juriloff D.M. Mouse mutants with neural tube closure defects and their role in understanding human neural tube defects. Birth Defects Res A: Clin Mol Teratol 2007, 79(3):187-210.
9. Jager-Roman E., et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986, 108(6):997-1004.
10. Okada A., et al. Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice. Birth Defects Res A: Clin Mol Teratol 2005, 73(4):229-238.
11. Kuo W.P., et al. A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies. Nat Biotechnol 2006, 24(7):832-840.
12. Downs K.M., Davies T. Staging of gastrulating mouse embryos by morphological landmarks in the dissecting microscope. Development 1993, 118(4):1255-1266.
13. Churchill G.A. Fundamentals of experimental design for cDNA microarrays. Nat Genet 2002 (Suppl. 32):490-5.
14. Su Y. et al. Rankgene: identication of diagnostic genes based on expression data; 2002.
15. Gentleman R.C., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5(10):R80.
16. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B (Methodological) 1995, 57(1):289-300.
17. R Development Core Team R: A language and environment for statistical computing 2006, R Foundation for Statistical Computing, Vienna, Austria.
18. Sturn A., Quackenbush J., Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002, 18(1):207-208.
19. Alvarez-Medina R., et al. Wnt canonical pathway restricts graded Shh/Gli patterning activity through the regulation of Gli3 expression. Development 2008, 135(2):237-247.
20. Ameur A., et al. The LCB Data Warehouse. Bioinformatics 2006, 22(8):1024-1026.
21. Calvano S.E., et al. A network-based analysis of systemic inflammation in humans. Nature 2005, 437(7061):1032-1037.
22. Abu-Abed S., et al. Differential expression of the retinoic acid-metabolizing enzymes CYP26A1 and CYP26B1 during murine organogenesis. Mech Dev 2002, 110(1-2):173-177.
23. Larkin J.E., et al. Independence and reproducibility across microarray platforms. Nat Methods 2005, 2(5):337-344.
24. Ehlers K., et al. Valproic acid-induced spina bifida: a mouse model. Teratology 1992, 45(2):145-154.
25. Faiella A., et al. A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression. Hum Mol Genet 2000, 9(2):227-236.
26. Chabanas A., et al. Effects of butyric acid on cell cycle regulation and induction of histone H1(0) in mouse cells and tissue culture. Inducibility of H1 (0)in the late S-G2 phase of the cell cycle. J Mol Biol 1985, 183(2):141-151.
27. Sourlingas T.G., Kypreou K.P., Sekeri-Pataryas K.E. The effect of the histone deacetylase inhibitor, trichostatin A, on total histone synthesis, H1(0) synthesis and histone H4 acetylation in peripheral blood lymphocytes increases as a function of increasing age: a model study. Exp Gerontol 2002, 37(2-3):341-348.
28. Gottlicher M., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20(24):6969-6978.
29. Phiel C.J., et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276(39):36734-36741.
30. Menegola E., et al. Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. Birth Defects Res B: Dev Reprod Toxicol 2005, 74(5):392-398.
31. Eikel D., Lampen A., Nau H. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol 2006, 19(2):272-278.
32. Gurvich N., et al. Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J 2005, 04-3425fje.
33. Svensson K., et al. The paternal allele of the H19 gene is progressively silenced during early mouse development: the acetylation status of histones may be involved in the generation of variegated expression patterns. Development 1998, 125(1):61-69.
34. Dawson J.E., Raymond A.M., Winn L.M. Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice. Toxicol Appl Pharmacol 2006, 211(2):124-132.
35. Rao J.S., et al. Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA. Bipolar Disord 2007, 9(5):513-520.
36. LaBonte M.J., et al. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 2009, 2:67.
37. Tergaonkar V. NFkappaB pathway: a good signaling paradigm and therapeutic target. Int J Biochem Cell Biol 2006, 38(10):1647-1653.
38. Shi L., et al. Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential. BMC Bioinform 2005, 6(Suppl. 2):S12.
39. Ewart J.L., et al. Heart and neural tube defects in transgenic mice overexpressing the Cx43 gap junction gene. Development 1997, 124(7):1281-1292.
40. Becker D.L., et al. Roles for alpha 1 connexin in morphogenesis of chick embryos revealed using a novel antisense approach. Dev Genet 1999, 24(1-2):33-42.
41. Simon A.M., et al. Heart and head defects in mice lacking pairs of connexins. Dev Biol 2004, 265(2):369-383.
42. Sheng G. Huntingtin-associated protein 1 interacts with Ahi1 to regulate cerebellar and brainstem development in mice. J Clin Investig 2008, 118(8):2785-2795.
43. Enkhmandakh B., et al. Essential functions of the Williams-Beuren syndrome-associated TFII-I genes in embryonic development. Proc Natl Acad Sci 2009, 106(1):181-186.
44. Bohm J., et al. Sall1, Sall2, and Sall4 are required for neural tube closure in mice. Am J Pathol 2008, 173(5):1455-1463.
45. Abu-Abed S., et al. The retinoic acid-metabolizing enzyme, CYP26A1, is essential for normal hindbrain patterning, vertebral identity, and development of posterior structures. Genes Dev 2001, 15(2):226-240.
46. Niederreither K., et al. Genetic evidence that oxidative derivatives of retinoic acid are not involved in retinoid signaling during mouse development. Nat Genet 2002, 31(1):84-88.
47. Tiboni G.M., Marotta F., Carletti E. Fluconazole alters CYP26 gene expression in mouse embryos. Reprod Toxicol 2009, 27(2):199-202.
48. Piedrahita J.A., et al. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat Genet 1999, 23(2):228-232.
49. Massari S S., et al. LIN7 mediates the recruitment of IRSp53 to tight junctions. Traffic 2009, 10(2):246-257.
50. Ang S., et al. Positive and negative signals from mesoderm regulate the expression of mouse Otx2 in ectoderm explants. Development 1994, 120(10):2979-2989.
51. Zakin L., et al. Gene expression profiles in normal and Otx2-/- early gastrulating mouse embryos. Proc Natl Acad Sci USA 2000, 97(26):14388-14393.
52. Gimeno L., Brûlet P., Martínez S. Study of Fgf15 gene expression in developing mouse brain. Gene Expr Patterns 2003, 3(4):473-481.